Montreal (Not currently accepting applications for 2025-2026. Please check back later.)

Shirin Golchi is an assistant professor of biostatistics at the Department of Epidemiology and Biostatistics, McGill University. Her research interests are Bayesian modelling and computation with a focus on Bayesian adaptive clinical trials. She graduated from Simon Fraser University with a PhD in statistics in 2014. Before coming to McGill she worked as a senior statistician at MTEK Sciences, a health research company which was later acquired by Cytel.

Shirin Golchi is an assistant professor of biostatistics at the Department of Epidemiology and Biostatistics, McGill University. Her research interests are Bayesian modelling and computation with a focus on Bayesian adaptive clinical trials. She graduated from Simon Fraser University with a PhD in statistics in 2014. Before coming to McGill she worked as a senior statistician at MTEK Sciences, a health research company which was later acquired by Cytel.

Dr. Hudson is a rheumatologist and clinician-scientist at the Jewish General Hospital and Lady Davis Institute, and an Associate professor and Member of the Division of Experimental Medicine in the Department of Medicine at McGill University. She pursues research in systemic autoimmune rheumatic diseases, including a feasibility study for an adaptive trial for rheumatoid arthritis and a Phase I/II Bayesian adaptive trial of umbilical cord-derived mesenchymal stromal cells in systemic sclerosis. Dr Hudson is also Co-Director of the McGill Interdisciplinary Initiative in Infection and Immunity which, since 2018, has provided over $34 million to support 130+ innovative research projects.

Dr. Hudson is a rheumatologist and clinician-scientist at the Jewish General Hospital and Lady Davis Institute, and an Associate professor and Member of the Division of Experimental Medicine in the Department of Medicine at McGill University. She pursues research in systemic autoimmune rheumatic diseases, including a feasibility study for an adaptive trial for rheumatoid arthritis and a Phase I/II Bayesian adaptive trial of umbilical cord-derived mesenchymal stromal cells in systemic sclerosis. Dr Hudson is also Co-Director of the McGill Interdisciplinary Initiative in Infection and Immunity which, since 2018, has provided over $34 million to support 130+ innovative research projects.